Sugi Predict

Sugi Predict / Targets / DPP3

DPP3

Dipeptidyl peptidase 3 · Q9NY33 · DPP3 on Sugi Atlas →

1,598 patent compounds predicted against DPP3, 1,121 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL29804127 SCHEMBL29804127 0.73 5/20
SCHEMBL29572021 SCHEMBL29572021 0.71 5/20
SCHEMBL19787869 SCHEMBL19787869 0.69 5/20
SCHEMBL29648960 SCHEMBL29648960 0.69 5/20
SCHEMBL29812309 SCHEMBL29812309 0.64 5/20
SCHEMBL29772689 SCHEMBL29772689 0.64 5/20
SCHEMBL29772690 SCHEMBL29772690 0.64 5/20
SCHEMBL17268807 SCHEMBL17268807 0.63 5/20
SCHEMBL29713766 SCHEMBL29713766 0.63 5/20
SCHEMBL29498733 SCHEMBL29498733 0.63 5/20
SCHEMBL29772691 SCHEMBL29772691 0.63 5/20
SCHEMBL29637421 SCHEMBL29637421 0.62 5/20
SCHEMBL29649746 SCHEMBL29649746 0.62 5/20
SCHEMBL11279290 SCHEMBL11279290 0.62 5/20
SCHEMBL29575470 SCHEMBL29575470 0.61 5/20
SCHEMBL12658503 SCHEMBL12658503 0.61 5/20
SCHEMBL15386490 SCHEMBL15386490 0.61 5/20
SCHEMBL29616317 SCHEMBL29616317 0.61 5/20
SCHEMBL29418184 SCHEMBL29418184 0.61 5/20
SCHEMBL29498754 SCHEMBL29498754 0.61 5/20

Clinical trials — most relevant to DPP3 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
The Effect of Sitagliptin, Pioglitazone and Dapagliflozine on Myocardial Infarction in Diabetic Rats PHASE4COMPLETED
SNP Study of DPP-4 and GLP-1R in Chinese People (Including Diabetes Patients) PHASE4COMPLETED
The Effect of Saxagliptin on Glucose Fluctuation and Immune Regulation in Patients With Type 1 Diabetes PHASE4UNKNOWN
Incretins in Impaired Fasting Glucose PHASE4COMPLETED
Correlation Between Plasma- and Endothelial DPP-4 Activity PHASE4COMPLETED
Metabolic and Cardiovascular Effects of Dipeptidyl Peptidase-4 (DPP-4) or Sodium-glucose Co-transporter Type 2 (SGLT2) Inhibitors PHASE4UNKNOWN
The INDORSE Study: Inhibition of Dipeptidyl Peptidase IV: Outcomes on Renal Sodium Excretion PHASE4COMPLETED
Evaluation of the DPP-4 Inhibitor Sitagliptin in the Treatment of Non-Alcoholic Fatty Liver Disease Using MRI PHASE4WITHDRAWN
Effect of Gemigliptin Versus Glimepiride on Cardiac Diastolic Function in Patients With Type 2 Diabetes PHASE4UNKNOWN
Comparing the Renal Effect of Dipeptidyl-peptidase 4 Inhibitors and Sulfonylureas PHASE4COMPLETED
Effect of Dipeptidyl Peptidase- 4 Inhibitors on Non-Alcoholic Steatohepatitis and Type 1 Diabetes PHASE3COMPLETED
Comparison Between Efficacy of Trelagliptin and Sitagliptin in Type II Diabetic Patients PHASE3ENROLLING_BY_INVITATION
The Effect of Sitagliptin Treatment in COVID-19 Positive Diabetic Patients PHASE3UNKNOWN
Long Term Effects of DPP-IV Inhibitor Treatment in Patients With Type 2 Diabetes PHASE3COMPLETED
Sitagliptin and Endothelial Dysfunction PHASE3UNKNOWN
Saxagliptin + Metformin Compared to Saxagliptin or Metformin Monotherapy in PCOS Women With Impaired Glucose Homeostasis PHASE3COMPLETED
Efficacy of SYR-472 in Subjects With Type 2 Diabetes Mellitus PHASE2COMPLETED
Efficacy and Safety of SYR-472 in Subjects With Type 2 Diabetes Mellitus PHASE2COMPLETED
Effect of Evogliptin on Albuminuria in Patients With Type 2 Diabetes and Renal Insufficiency PHASE2COMPLETED
Effect of Aqueous Extracts of Cissus Quadrangularis and Dichrostachys Glomerata on GLP-1 Concentration and DPP-4 Activity in Overweight and Obese Adults PHASE1/PHASE2ACTIVE_NOT_RECRUITING
Effect of Sitagliptin on Incretin Effect in Patients With Type 2 Diabetes Mellitus PHASE1COMPLETED
DPP4 Activity, Microvascular Reactivity and Inflammation nanCOMPLETED
The Incretin Effect in Patients With Kidney Impairment nanCOMPLETED
Influence of DPP-4 on Inflammatory Parameters in Diabetics: Gender Aspects nanUNKNOWN
Effect of Dipeptidyl Peptidase IV After Diets in näive Type 2 Diabetic Patients nanCOMPLETED
Emulation of the SOUL Diabetes Trial in Healthcare Claims nanCOMPLETED
Plasma Dipeptidyl-peptidase-4 Activities With No-reflow and Bleeding nanCOMPLETED
Effect of Chronic ACE and DPP4 Inhibition on Blood Pressure nanCOMPLETED
Emulating the PIONEER6 Diabetes Trial Using Healthcare Claims nanCOMPLETED
Perioperative Sitagliptin Medication for Reduction of the Inflammatory Response Associated With Cardiopulmonary Bypass nanCOMPLETED

Related proteins — ESM-2 sequence neighbours (a DPP3 binder may also engage these)

ProteinNameSimilarity
O55096 — 1.000 O55096 →
Q99KK7 — 1.000 Q99KK7 →
A7RZW4 — 0.992 A7RZW4 →
Q9VHR8 — 0.986 Q9VHR8 →
Q557H1 — 0.983 Q557H1 →
Q8L831 — 0.982 Q8L831 →
A7KAL8 — 0.982 A7KAL8 →
Q09WE7 — 0.980 Q09WE7 →
Q52CS0 — 0.980 Q52CS0 →
Q0GZS3 — 0.979 Q0GZS3 →
H1AE13 — 0.979 H1AE13 →
A0A4P8DJE6 — 0.979 A0A4P8DJE6 →
M7U9B9 — 0.979 M7U9B9 →
A7EI75 — 0.979 A7EI75 →
Q2UCL6 — 0.978 Q2UCL6 →
P0CT06 — 0.978 P0CT06 →
L7HUY5 — 0.978 L7HUY5 →
A4RHN5 — 0.978 A4RHN5 →
Q4HYR2 — 0.978 Q4HYR2 →
P93028 — 0.978 P93028 →
P0C153 — 0.978 P0C153 →
F7W4M2 — 0.978 F7W4M2 →
O53611 — 0.978 O53611 →
G2XR75 — 0.978 G2XR75 →
A8NR45 — 0.977 A8NR45 →
O88428 — 0.977 O88428 →
Q08225 — 0.977 Q08225 →
P28240 — 0.977 P28240 →
Q9HZP8 — 0.977 Q9HZP8 →
P17289 — 0.977 P17289 →